Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Tuesday reported positive three-year antibody persistence data for its single-dose chikungunya vaccine, IXCHIQ.
The data demonstrated sustained high levels of neutralising antibodies in both younger and older adults.
These findings confirm the long-lasting protective immunity induced by IXCHIQ, reinforcing its potential to significantly reduce the burden of chikungunya disease.
The IXCHIQ vaccine is currently approved in the United States, Europe and Canada for adults aged 18 and older. Valneva is pursuing label extensions to include adolescents and is working to expand access to the vaccine in low and middle-income countries.
hVIVO completes pilot study for hMPV challenge model
Merck's Gardasil approved for males in China
Brii Bio acquires BRII-179 IP rights
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Sanofi's combination vaccine candidates for flu and COVID-19 get Fast Track Designation
hVIVO secures GBP11.5m RSV contract
Novavax sells Czech manufacturing site to Novo Nordisk for USD200m
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine